It may be time to schedule that check-in with your cardiologist – yes, even if you're in your 30s. In a significant move to combat and prevent high cholesterol levels, the American Heart Association, American College of Cardiology, and nine other institutions recently released new guidelines, including two blood tests.
The announcement, the first update in nearly 10 years, focuses on early intervention and prevention for dyslipidemia, or abnormal levels of lipids like cholesterol and triglycerides in the blood. High levels of lipoprotein-cholesterol (LDL-C) or "bad cholesterol" affect 25% of American adults and increase the risk of heart attack and stroke.
While the bottom line of the guidelines is that heart disease prevention needs to begin earlier in life, the standout sections to me, as a board-certified cardiologist that focuses on prevention and exercise, include understanding lifetime cholesterol exposure, a new risk calculator, two new biomarker screening tests, and a personalized approach to understanding a patient’s risk.
One of the most important shifts in these guidelines is recognizing that cumulative exposure to cholesterol over your lifetime matters more than just your current levels. Think of it like compound interest — the longer you're exposed to elevated cholesterol, even at levels previously considered "normal," the more damage accumulates in your arteries. This is why the guidelines now recommend screening starting at age 19, with repeat testing every five years for young adults. The focus has shifted from simply treating high numbers to minimizing lifetime exposure to the cholesterol particles that cause heart disease.
Your cardiologist may use a different assessment tool at your next appointment, especially if you're in your 30s. The newer Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator is significantly more accurate than the old equations.
Here's the important part: because PREVENT provides more accurate estimates, it actually means fewer people will be recommended for medications. Studies show that approximately 17 million Americans who would have been recommended statins under the old calculator may no longer need them with PREVENT. This doesn't mean we're being less aggressive about prevention — it means we're being smarter about identifying who truly benefits from treatment.
The PREVENT calculator also assesses risk over the next 30 years for younger adults, not just 10 years. This longer-term view is particularly helpful for people in their 30s, 40s, and 50s, where a conversation about your cardiovascular health trajectory over decades — not just the next few years — can motivate meaningful lifestyle changes now.
In addition to the PREVENT calculator, another standout in the guidelines is the testing recommendation for two biomarkers in the blood. These tests give us far more information than LDL cholesterol alone.
Apolipoprotein B (apoB) measures the actual number of harmful cholesterol particles in your blood, not just the amount of cholesterol. This distinction is crucial. You can have "normal" LDL cholesterol but still have too many particles that can damage your arteries — a situation that's especially common in people with diabetes, metabolic syndrome, or elevated triglycerides. ApoB tells us the residual risk once LDL levels are controlled. So even if a patient has successfully managed their "bad cholesterol," if the apoB is still high, we know we need to be more aggressive to achieve better protection. Research shows that apoB is particularly valuable in younger adults for identifying those who would benefit most from early intervention.
The second suggested test is for lipoprotein(a), which should be measured at least once in everyone's lifetime. This genetically determined cholesterol particle increases heart disease risk by about 40% when elevated. While we don't yet have medications that directly lower Lp(a), knowing it's elevated allows us to be more aggressive with the risk factors we can control — like LDL cholesterol, blood pressure, and lifestyle factors.
Both tests will ideally be part of the standard lipid panel in the future, but for now, they are separate send-out tests. Because they are included in these recommendations, they should be covered by insurance.
Perhaps the most important evolution in these guidelines is the emphasis on personalizing your cardiovascular care. The guidelines recognize that risk calculators don't capture everything about an individual's risk. That's where "risk enhancers" come in — factors that may tip the balance toward starting or intensifying treatment.
Risk enhancers include:
The presence of one or more of these factors helps your doctor personalize your treatment plan, especially if your calculated risk falls in the borderline range (3-5% 10-year risk). This individualized approach means treatment decisions are based on your complete picture — not just a number from a calculator.
Overall, these recommendations show us that we need to think earlier, smarter, and more personally about prevention of heart disease. The new tools (PREVENT calculator, apoB, and Lp(a) testing) give us unprecedented ability to identify who will benefit most from treatment while avoiding overtreatment of those at lower risk. If anything, they can help jump-start the heart-health conversation between patients and doctors, focusing on your unique risk profile and lifetime cardiovascular health trajectory.
The announcement, the first update in nearly 10 years, focuses on early intervention and prevention for dyslipidemia, or abnormal levels of lipids like cholesterol and triglycerides in the blood. High levels of lipoprotein-cholesterol (LDL-C) or "bad cholesterol" affect 25% of American adults and increase the risk of heart attack and stroke.
While the bottom line of the guidelines is that heart disease prevention needs to begin earlier in life, the standout sections to me, as a board-certified cardiologist that focuses on prevention and exercise, include understanding lifetime cholesterol exposure, a new risk calculator, two new biomarker screening tests, and a personalized approach to understanding a patient’s risk.
Understanding Lifetime Cholesterol Exposure
One of the most important shifts in these guidelines is recognizing that cumulative exposure to cholesterol over your lifetime matters more than just your current levels. Think of it like compound interest — the longer you're exposed to elevated cholesterol, even at levels previously considered "normal," the more damage accumulates in your arteries. This is why the guidelines now recommend screening starting at age 19, with repeat testing every five years for young adults. The focus has shifted from simply treating high numbers to minimizing lifetime exposure to the cholesterol particles that cause heart disease.
New Equation For Calculating Risk — And Why Fewer People May Need Medications
Your cardiologist may use a different assessment tool at your next appointment, especially if you're in your 30s. The newer Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator is significantly more accurate than the old equations.
Here's the important part: because PREVENT provides more accurate estimates, it actually means fewer people will be recommended for medications. Studies show that approximately 17 million Americans who would have been recommended statins under the old calculator may no longer need them with PREVENT. This doesn't mean we're being less aggressive about prevention — it means we're being smarter about identifying who truly benefits from treatment.
The PREVENT calculator also assesses risk over the next 30 years for younger adults, not just 10 years. This longer-term view is particularly helpful for people in their 30s, 40s, and 50s, where a conversation about your cardiovascular health trajectory over decades — not just the next few years — can motivate meaningful lifestyle changes now.
Two New Biomarker Tests: Going Beyond LDL Cholesterol
In addition to the PREVENT calculator, another standout in the guidelines is the testing recommendation for two biomarkers in the blood. These tests give us far more information than LDL cholesterol alone.
Apolipoprotein B (apoB) measures the actual number of harmful cholesterol particles in your blood, not just the amount of cholesterol. This distinction is crucial. You can have "normal" LDL cholesterol but still have too many particles that can damage your arteries — a situation that's especially common in people with diabetes, metabolic syndrome, or elevated triglycerides. ApoB tells us the residual risk once LDL levels are controlled. So even if a patient has successfully managed their "bad cholesterol," if the apoB is still high, we know we need to be more aggressive to achieve better protection. Research shows that apoB is particularly valuable in younger adults for identifying those who would benefit most from early intervention.
The second suggested test is for lipoprotein(a), which should be measured at least once in everyone's lifetime. This genetically determined cholesterol particle increases heart disease risk by about 40% when elevated. While we don't yet have medications that directly lower Lp(a), knowing it's elevated allows us to be more aggressive with the risk factors we can control — like LDL cholesterol, blood pressure, and lifestyle factors.
Both tests will ideally be part of the standard lipid panel in the future, but for now, they are separate send-out tests. Because they are included in these recommendations, they should be covered by insurance.
A Personalized Approach Using Risk Enhancers
Perhaps the most important evolution in these guidelines is the emphasis on personalizing your cardiovascular care. The guidelines recognize that risk calculators don't capture everything about an individual's risk. That's where "risk enhancers" come in — factors that may tip the balance toward starting or intensifying treatment.
Risk enhancers include:
- Family history of early heart disease (before age 55 in men, 65 in women).
- Chronic inflammatory conditions like rheumatoid arthritis, lupus, or psoriasis.
- Reproductive history for women, including early menopause (before 45), preeclampsia, gestational diabetes, or preterm delivery.
- Elevated Lp(a) or apoB levels.
- Chronic kidney disease or metabolic syndrome.
- Persistently elevated LDL cholesterol (160-189 mg/dL) or triglycerides.
- Higher-risk ancestry (South Asian or Filipino).
- Elevated inflammatory markers like high-sensitivity C-reactive protein.
The presence of one or more of these factors helps your doctor personalize your treatment plan, especially if your calculated risk falls in the borderline range (3-5% 10-year risk). This individualized approach means treatment decisions are based on your complete picture — not just a number from a calculator.
The Bottom Line
Overall, these recommendations show us that we need to think earlier, smarter, and more personally about prevention of heart disease. The new tools (PREVENT calculator, apoB, and Lp(a) testing) give us unprecedented ability to identify who will benefit most from treatment while avoiding overtreatment of those at lower risk. If anything, they can help jump-start the heart-health conversation between patients and doctors, focusing on your unique risk profile and lifetime cardiovascular health trajectory.
Featured Expert/ Author
)
